Dr Reddy’s Laboratories inks pact with Amgen to commercialise three drugs in India Industry-The Economic Times — September 16, 2016 comments off Under the terms, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said today.
Under the terms, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said today.